Funding news · Oct 22, 2026
Boltz PBC Raises $97.4M Series C+ to Advance Open Biomolecular AI Models
Boltz PBC Secures $97.4M in Series C+ Funding
Boltz PBC has raised $97.4 million in a Series C+ round, according to funding data dated October 22, 2026. The round was backed by NVIDIA.
What Boltz PBC Does
Boltz PBC builds open biomolecular AI models and platforms for drug discovery. Its work spans three core capabilities:
- Structure prediction — modeling biomolecular structures
- Affinity estimation — assessing binding affinity
- Generative design — generating novel molecular designs
The company also offers hosted agents for scientists, giving research teams access to these capabilities through a platform rather than requiring them to build and run models themselves.
Round Details
| Item | Detail |
|---|---|
| Company | Boltz PBC |
| Round type | Series C+ |
| Amount | $97.4M USD |
| Funding date | October 22, 2026 |
| Investors | NVIDIA |
| Domain | boltz.bio |
No lead investor was specified in the funding data for this round.
Why the Positioning Matters
Boltz PBC sits at the intersection of two trends relevant to strategic and acquisition-oriented observers: the application of AI models to drug discovery workflows, and the open-model approach to biomolecular tooling. By building open models alongside hosted agents for scientists, the company targets both the underlying model layer and the practical interface researchers use day to day.
The involvement of NVIDIA as an investor is notable given the compute-intensive nature of biomolecular modeling and generative design. The funding data does not disclose the specific terms, valuation, or strategic rationale behind the investment.
What the Data Does Not Say
This report is limited to the disclosed funding payload. The available data does not include:
- A named lead investor
- Customer or partnership announcements
- Product roadmap details beyond the described model and platform capabilities
- Use-of-proceeds plans
Summary
Boltz PBC has raised a $97.4 million Series C+ round with NVIDIA as an investor, as of October 22, 2026. The company develops open biomolecular AI models and platforms for drug discovery, covering structure prediction, affinity estimation, and generative design, with hosted agents for scientists. For parties tracking the biomolecular AI space, the round represents a substantial capital event at a late stage for a company building open models and scientist-facing tooling in the same stack.